NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
Sixth Affiliated Hospital, Sun Yat-sen University
UNICANCER
Radiation Therapy Oncology Group
National Cancer Institute (NCI)